CAMBRIDGE, Mass., Nov. 1, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the appointment of Eric Shaff, Chief Financial Officer of Seres Therapeutics (NASDAQ:MCRB), to the Sigilon Therapeutics board of directors. Mr. Shaff brings a long history of industry experience to the company’s board.
“Mr. Shaff’s experience in company building, finance, and corporate development, notably in emerging areas of biotechnology, will be particularly helpful as we develop a new Afibromer™ cell factory approach to the treatment of chronic diseases,” said Douglas Cole, M.D., Chairman of the Board of Sigilon Therapeutics. “We are pleased that Mr. Shaff will share his perspectives and experience as a member of the board and appreciate his recognition of the promise of Sigilon’s technology platform.”
Mr. Shaff commented, “I am excited to contribute to the Company’s plans to harness the full power of ‘living therapeutics’ to make a meaningful difference for patients with serious and chronic unmet needs.”
Eric Shaff is Executive Vice President and Chief Financial Officer of Seres Therapeutics, a role that follows a series of leadership positions in corporate finance in the biopharmaceutical industry. Prior to Seres, Mr. Shaff worked at Momenta Pharmaceuticals and Genzyme Corporation, where he served as global head of finance of Genzyme’s Rare Genetic Disease Division in addition to roles in corporate development and corporate finance. Mr. Shaff has also worked in corporate finance at Pfizer and in investment banking with Broadview International (now Jefferies Broadview). Mr. Shaff earned a B.A. from the University of Pennsylvania and holds an M.B.A. from the Johnson Graduate School of Management at Cornell University.
About Sigilon Therapeutics
Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer ™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.
In addition to Flagship Pioneering, Sigilon Therapeutics’ co-founders include Daniel Anderson, Ph.D., and Robert Langer, Sc.D. of MIT’s Institute of Medical Engineering and Science, Department of Chemical Science and Koch Institute; Omid Veiseh, Ph.D., of Rice University; José Oberholzer, M.D., of the University of Virginia; and Arturo Vegas, Ph.D., of Boston University.